What question did this study set out to answer?

June 1, 2026Cell TransplantationOpen Access

Analysis of the efficacy and survival of allogeneic hematopoietic stem cell transplantation and nontransplantation treatment in chronic active Epstein–Barr virus infection

View Full Paper

Ask AI

Bookmark

This study aims to compare the efficacy and survival outcomes of allogeneic HSCT and PD-1 blockade therapy in patients with chronic active Epstein–Barr virus infection.
Retrospective analysis of 75 patients with chronic active Epstein–Barr virus infection.
Patients classified into allogeneic HSCT and non-HSCT groups.
Primary endpoints included overall response rate, overall survival, and event-free survival.
HSCT significantly improved overall response rate and 3-year overall survival compared to non-HSCT; p-values not specified.
In patients without hemophagocytic lymphohistiocytosis (HLH), HSCT remained superior overall.
HLH identified as an independent risk factor for poorer survival.

No takes yet. Share an insight, caveat, or question.

Retrospective study compares survival outcomes of allogeneic HSCT and PD-1 blockade therapy in CAEBV, highlighting HSCT as the superior option.

Ming et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective study compares survival outcomes of allogeneic HSCT and PD-1 blockade therapy in CAEBV, highlighting HSCT as the superior option.